STIM - Neuronetics, Inc Stock Price, Fair Value and News

3.48USD-0.04 (-1.14%)Market Closed

Market Summary

USD3.48-0.04

Market Closed

-1.14%

STIM Stock Price

View Fullscreen

STIM RSI Chart

STIM Valuation

Market Cap

103.6M

Price/Earnings (Trailing)

-3.43

Price/Sales (Trailing)

1.45

Price/Free Cashflow

-3.23

STIM Price/Sales (Trailing)

STIM Profitability

Operating Margin

82.55%

Return on Equity

-88.3%

Return on Assets

-26.06%

Free Cashflow Yield

-30.94%

STIM Fundamentals

STIM Revenue

Revenue (TTM)

71.3M

Rev. Growth (Yr)

11.63%

Rev. Growth (Qtr)

13.59%

STIM Earnings

Earnings (TTM)

-30.2M

Earnings Growth (Yr)

35.14%

Earnings Growth (Qtr)

42.74%

Breaking Down STIM Revenue

Last 7 days

-8.4%

Last 30 days

-27.5%

Last 90 days

3.9%

Trailing 12 Months

54.0%

How does STIM drawdown profile look like?

STIM Financial Health

Current Ratio

4.73

Debt/Equity

1.73

Debt/Cashflow

-0.54

STIM Investor Care

Shares Dilution (1Y)

4.91%

Diluted EPS (TTM)

-1.06

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	66.6M	67.8M	69.2M	71.3M
2022	57.2M	59.3M	62.0M	65.2M
2021	50.1M	54.5M	55.9M	55.3M
2020	61.4M	54.6M	51.0M	49.2M
2019	55.4M	58.7M	60.9M	62.7M
2018	43.1M	46.0M	49.2M	52.8M
2017	35.8M	37.3M	38.9M	40.4M
2016	0	0	0	34.2M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Neuronetics, Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Feb 29, 2024	macan william andrew	sold	-17,716	2.94	-6,026	evp, gc, cco and cs
Feb 29, 2024	macan william andrew	acquired	-	-	15,000	evp, gc, cco and cs
Feb 29, 2024	furlong stephen	acquired	-	-	15,000	evp, cfo and treasurer
Feb 28, 2024	macan william andrew	sold	-70,711	3.16	-22,377	evp, gc, cco and cs
Feb 28, 2024	furlong stephen	sold	-12,592	3.16	-3,985	evp, cfo and treasurer
Feb 27, 2024	furlong stephen	sold	-70,835	3.33	-21,272	evp, cfo and treasurer
Feb 26, 2024	sullivan keith j	sold	-66,963	3.3	-20,292	president and ceo
Feb 23, 2024	sullivan keith j	sold	-67,022	3.23	-20,750	president and ceo
Feb 22, 2024	sullivan keith j	sold	-67,348	3.23	-20,851	president and ceo
Feb 20, 2024	sullivan keith j	sold	-70,915	2.96	-23,958	president and ceo

Which funds bought or sold STIM recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 25, 2024	Bank of New York Mellon Corp	reduced	-18.71	57,443	229,256	-%
Apr 25, 2024	SIMPLEX TRADING, LLC	sold off	-100	-15,000	-	-%
Apr 25, 2024	Fielder Capital Group LLC	unchanged	-	42,403	108,514	0.05%
Apr 24, 2024	Assenagon Asset Management S.A.	reduced	-3.33	146,619	396,489	-%
Apr 17, 2024	CRITERION CAPITAL ADVISORS, LLC	unchanged	-	744	1,904	-%
Apr 16, 2024	MCF Advisors LLC	unchanged	-	10,349	26,485	-%
Apr 11, 2024	David J Yvars Group	reduced	-6.95	114,570	331,867	0.22%
Apr 11, 2024	OPTIMUM INVESTMENT ADVISORS	unchanged	-	372	952	-%
Apr 10, 2024	ATWOOD & PALMER INC	unchanged	-	186	476	-%
Apr 05, 2024	CWM, LLC	new	-	-	-	-%

Are Funds Buying or Selling STIM?

Are funds buying STIM calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own STIM

No. of Funds

Unveiling Neuronetics, Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Apr 01, 2024	divisadero street capital management, lp	5.2%	1,539,382	SC 13G
Feb 14, 2024	kent lake capital llc	3.9%	1,116,041	SC 13G/A
Feb 13, 2024	cannell capital llc	9.57%	2,769,268	SC 13G/A
Feb 13, 2024	archon capital management llc	8.77%	2,537,097	SC 13G/A
Sep 22, 2023	kent lake capital llc	5.5%	1,600,100	SC 13G
Sep 11, 2023	cannell capital llc	9.80%	2,828,655	SC 13G
Aug 23, 2023	archon capital management llc	9.97%	2,877,706	SC 13G/A
Aug 17, 2023	cannell capital llc	8.45%	2,440,536	SC 13D/A
Jun 09, 2023	cannell capital llc	9.97%	2,841,223	SC 13D/A
Mar 23, 2023	cannell capital llc	11.03%	3,127,819	SC 13D/A

Recent SEC filings of Neuronetics, Inc

View All Filings

Date Filed	Form Type	Document
Apr 11, 2024	DEF 14A	DEF 14A
Apr 11, 2024	DEFA14A	DEFA14A
Apr 01, 2024	SC 13G	Major Ownership Report
Mar 28, 2024	8-K	Current Report
Mar 25, 2024	8-K	Current Report
Mar 08, 2024	10-K	Annual Report
Mar 06, 2024	8-K	Current Report
Mar 05, 2024	8-K	Current Report
Mar 05, 2024	8-K	Current Report
Mar 01, 2024	4	Insider Trading

Peers (Alternatives to Neuronetics, Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
DHR	182.5B	23.7B	-0.93%	6.50%	41.46	7.69	-8.94%	-35.72%
IDXX	41.5B	3.7B	-7.44%	3.05%	49.1	11.33	8.72%	24.44%
A	40.3B	6.7B	-6.59%	3.31%	32.64	5.99	-2.81%	-6.58%
DGX	14.9B	9.3B	2.40%	-4.82%	17.61	1.6	-3.29%	6.68%
MEDP	12.3B	2.0B	-1.91%	100.24%	39.22	6.24	25.57%	21.62%
CRL	11.8B	4.1B	-15.01%	24.62%	24.77	2.85	3.86%	-2.39%
NTRA	11.1B	1.1B	1.32%	82.46%	-25.45	10.22	31.99%	20.63%
EXAS	10.7B	2.5B	-11.98%	-7.20%	-52.35	4.28	19.93%	67.26%
MID-CAP
NEOG	2.6B	929.2M	-21.41%	-29.07%	1.7K	2.83	28.93%	111.61%
GH	2.1B	563.9M	-3.40%	-19.97%	-4.4	3.74	25.45%	26.76%
SMALL-CAP
CDNA	390.9M	280.3M	-28.23%	-2.96%	-2.05	1.39	-12.89%	-148.37%
ACRS	84.4M	31.2M	-5.56%	-86.21%	-0.95	2.7	5.03%	-1.81%
APDN	74.2M	9.0M	918.60%	338.04%	-10.27	8.25	-53.31%	2.21%
AWH	41.1M	9.2M	-2.92%	-32.04%	-2.46	4.49	11.85%	44.12%
BIOC	183.8K	25.9M	-50.00%	-94.83%	-0.01	0.01	-57.78%	-93.11%

Neuronetics, Inc News

Latest updates

Neuronetics, Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Revenue	13.6%	20,314,000	17,884,000	17,610,000	15,540,000	18,198,000	16,498,000	16,329,000	14,181,000	15,022,000	13,799,000	14,203,000	12,288,000	15,579,000	12,448,000	9,741,000	11,476,000	17,356,000	16,000,000	16,572,000	12,728,000	15,635,000
Cost Of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3,711,000
Gross Profit	34.1%	15,771,000	11,764,000	12,774,000	11,396,000	13,808,500	12,928,000	12,290,000	10,696,000	11,484,000	10,655,000	11,453,000	10,067,000	11,816,000	9,791,000	7,418,000	8,665,000	13,137,000	11,808,000	12,401,000	9,921,000	11,924,000
Operating Expenses	-2.1%	20,198,000	20,635,000	20,123,000	21,303,000	21,535,000	20,382,000	22,086,000	20,831,000	18,393,000	17,837,000	18,017,000	16,976,000	14,476,000	12,215,000	14,277,000	19,031,000	20,076,000	18,136,000	19,008,000	16,977,000	17,585,000
S&GA Expenses	-3.5%	11,716,000	12,141,000	11,559,000	11,902,000	12,005,000	11,643,000	13,685,000	12,649,000	10,315,500	9,827,000	9,042,000	8,561,000	7,635,000	6,053,000	8,151,000	10,723,000	11,516,000	10,362,000	11,523,000	9,592,000	10,648,000
R&D Expenses	2.4%	2,206,500	2,155,000	2,364,000	2,790,000	3,139,500	2,348,000	2,045,000	1,803,000	1,743,500	1,575,000	2,294,000	2,311,000	2,112,000	1,952,000	2,116,000	3,021,000	4,248,000	3,489,000	3,224,000	2,786,000	2,222,000
EBITDA Margin	-	-	-	-	-	-	-	-	-	-	-0.43	-0.44	-0.48	-0.48	-0.46	-0.43	-0.38	-0.39	-0.32	-0.33	-0.35	-0.37
Interest Expenses	55.7%	1,843,500	1,184,000	1,144,000	1,253,000	1,212,000	1,061,000	1,000,000	978,000	1,064,000	993,000	977,000	985,000	1,011,000	1,002,000	986,000	1,523,000	905,000	930,000	931,000	919,000	939,000
EBT Margin	-	-	-	-	-	-	-	-	-	-	-0.52	-0.53	-0.58	-0.59	-0.57	-0.53	-0.47	-0.46	-0.40	-0.41	-0.44	-0.46
Net Income	42.7%	-5,377,000	-9,391,000	-4,901,000	-10,520,000	-8,290,000	-7,609,000	-10,422,000	-10,838,000	-7,636,000	-8,151,000	-7,525,000	-7,881,000	-3,657,000	-3,418,000	-7,765,000	-12,613,000	-7,554,000	-6,867,000	-7,094,000	-7,529,000	-6,143,000
Net Income Margin	11.5%	-0.42	-0.48	-0.46	-0.55	-0.57	-0.59	-0.62	-0.60	-0.56	-0.49	-0.41	-0.45	-	-	-	-	-	-	-	-	-
Free Cashflow	121.3%	2,162,000	-10,153,000	-8,847,000	-15,200,000	-3,061,000	-6,507,000	-8,950,000	-12,182,000	-4,541,000	-8,519,000	-5,772,000	-9,168,000	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	24.6%	116	93.00	100	104	117	119	123	130	141	143	148	152	79.00	78.00	80.00	88.00	100	105	109	113	117
Current Assets	32.1%	94.00	71.00	78.00	81.00	99.00	101	95.00	103	115	119	135	139	65.00	65.00	67.00	76.00	88.00	96.00	101	106	114
Cash Equivalents	66.5%	60.00	36.00	46.00	55.00	70.00	74.00	71.00	81.00	94.00	99.00	116	121	49.00	51.00	54.00	64.00	76.00	82.00	90.00	96.00	105
Inventory	-16.9%	8.00	10.00	9.00	9.00	9.00	9.00	7.00	8.00	7.00	5.00	5.00	5.00	4.00	4.00	3.00	3.00	3.00	3.00	3.00	2.00	2.00
Net PPE	-2.8%	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
Liabilities	48.3%	82.00	55.00	55.00	55.00	60.00	56.00	55.00	53.00	56.00	52.00	51.00	50.00	53.00	51.00	51.00	52.00	52.00	51.00	50.00	48.00	46.00
Current Liabilities	29.2%	20.00	15.00	15.00	15.00	33.00	25.00	19.00	13.00	16.00	48.00	12.00	11.00	14.00	46.00	45.00	12.00	28.00	22.00	17.00	12.00	14.00
Long Term Debt	60.9%	59.00	37.00	37.00	37.00	23.00	27.00	31.00	35.00	35.00	-	35.00	35.00	35.00	-	-	34.00	20.00	23.00	27.00	31.00	30.00
LT Debt, Current	-	-	-	-	-	13.00	9.00	4.00	-	-	35.00	-	-	-	35.00	34.00	-	11.00	8.00	4.00	-	-
LT Debt, Non Current	60.9%	59.00	37.00	37.00	37.00	23.00	27.00	31.00	35.00	35.00	-	35.00	35.00	35.00	-	-	34.00	20.00	23.00	27.00	31.00	30.00
Shareholder's Equity	-9.9%	34.00	38.00	45.00	48.00	57.00	63.00	68.00	77.00	85.00	91.00	97.00	102	25.00	27.00	29.00	37.00	48.00	54.00	60.00	65.00	71.00
Retained Earnings	-1.5%	-376	-370	-361	-356	-345	-337	-329	-319	-308	-301	-292	-285	-277	-273	-270	-262	-250	-242	-235	-228	-221
Additional Paid-In Capital	0.4%	410	408	407	404	403	400	398	396	394	392	390	387	303	301	300	299	298	297	295	294	292
Shares Outstanding	0.7%	29.00	29.00	29.00	28.00	27.00	27.00	27.00	27.00	25.00	25.00	26.00	25.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	57.00	-	-	-	68.00	-	-	-	396	-	-	-	33.00	-	-	-	226	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	121.2%	2,162	-10,200	-8,787	-15,213	-3,100	-6,507	-8,950	-12,182	-4,541	-8,519	-5,772	-9,168	-1,713	-3,556	-9,481	-13,650	-6,403	-7,661	-6,848	-9,570	-2,276
Share Based Compensation	-12.3%	1,626	1,855	2,033	1,805	2,113	2,178	2,203	2,252	1,703	1,961	2,009	2,196	1,516	1,046	646	1,196	976	935	1,022	501	379
Cashflow From Investing	-953.0%	-563	66.00	-642	-183	-503	9,274	-966	-1,074	-801	-7,930	-433	-675	-115	-131	-218	-266	-359	-56.00	-124	-274	-361
Cashflow From Financing	-	22,260	-	-62.00	499	245	-	10.00	-48.00	32.00	100	711	82,163	56.00	410	48.00	1,855	100	443	470	1,407	460

STIM Income Statement

2023-12-31

Statements of Operations - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Statements of Operations
Revenues	$ 71,348	$ 65,206	$ 55,312
Cost of revenues	19,643	15,483	11,653
Gross profit	51,705	49,723	43,659
Operating expenses:
Sales and marketing	47,318	49,982	37,746
General and administrative	25,426	25,516	25,554
Research and development	9,515	9,336	7,923
Total operating expenses	82,259	84,834	71,223
Loss from operations	(30,554)	(35,111)	(27,564)
Other (income) expense:
Interest expense	5,424	4,251	4,019
Other income, net	(5,789)	(2,203)	(390)
Net loss	$ (30,189)	$ (37,159)	$ (31,193)
Net loss per share of common stock outstanding, basic	$ (1.05)	$ (1.38)	$ (1.22)
Net loss per share of common stock outstanding, diluted	$ (1.05)	$ (1.38)	$ (1.22)
Weighted-average common shares outstanding, basic	28,658	26,900	25,479
Weighted-average common shares outstanding, diluted	28,658	26,900	25,479

STIM Balance Sheet

2023-12-31

Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 59,677	$ 70,340
Accounts receivable, net	15,782	13,591
Inventory	8,093	8,899
Current portion of net investments in sales-type leases	905	1,538
Current portion of prepaid commission expense	2,514	1,997
Current portion of notes receivable	2,056	230
Prepaid expenses and other current assets	4,766	2,174
Total current assets	93,793	98,769
Property and equipment, net	2,009	1,991
Operating lease right-of-use assets	2,773	3,327
Net investments in sales-type leases	661	1,222
Prepaid commission expense	8,370	7,568
Long-term notes receivable	3,795	362
Other assets	4,430	3,645
Total Assets	115,831	116,884
Current liabilities:
Accounts payable	4,752	2,433
Accrued expenses	12,595	14,837
Deferred revenue	1,620	1,980
Current portion of operating lease liabilities	845	824
Current portion of long-term debt, net		13,125
Total current liabilities	19,812	33,199
Long-term debt, net	59,283	22,829
Deferred revenue	200	829
Operating lease liabilities	2,346	2,967
Total liabilities	81,641	59,824
Commitments and contingencies (Note 18)
Stockholders' equity:
Preferred stock, $0.01 par value: 10,000 shares authorized; no shares issued or outstanding on December 31, 2023, and December 31, 2022
Common stock, $0.01 par value: 200,000 shares authorized; 29,092 and 27,268 shares issued and outstanding on December 31, 2023, and December 31, 2022, respectively	291	273
Additional paid-in capital	409,980	402,679
Accumulated deficit	(376,081)	(345,892)
Total Stockholders' equity	34,190	57,060
Total Liabilities and Stockholders' equity	$ 115,831	$ 116,884

About Neuronetics, Inc

Neuronetics, Inc., a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company sells its products through its sales and customer support team to psychiatrists. Neuronetics, Inc. was incorporated in 2001 and is headquartered in Malvern, Pennsylvania.

CEO	Mr. Keith J. Sullivan
WEBSITE	https://neurostar.com
INDUSTRY	Diagnostics & Research
EMPLOYEES	209

Neuronetics, Inc Frequently Asked Questions

What is the ticker symbol for Neuronetics, Inc? What does STIM stand for in stocks?

STIM is the stock ticker symbol of Neuronetics, Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Neuronetics, Inc (STIM)?

As of Fri Apr 26 2024, market cap of Neuronetics, Inc is 103.55 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of STIM stock?

You can check STIM's fair value in chart for subscribers.

What is the fair value of STIM stock?

You can check STIM's fair value in chart for subscribers. The fair value of Neuronetics, Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Neuronetics, Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for STIM so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Neuronetics, Inc a good stock to buy?

The fair value guage provides a quick view whether STIM is over valued or under valued. Whether Neuronetics, Inc is cheap or expensive depends on the assumptions which impact Neuronetics, Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for STIM.

What is Neuronetics, Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Apr 26 2024, STIM's PE ratio (Price to Earnings) is -3.43 and Price to Sales (PS) ratio is 1.45. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. STIM PE ratio will change depending on the future growth rate expectations of investors.